Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $8.00 price target on the stock.
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates [Yahoo! Finance]
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $8.00 price target on the stock.
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates